Plunkett Research Online: Editas Medicine Inc

EDITAS MEDICINE INC (EDIT:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR.....



Editas Medicine Inc
Ticker: EDIT
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617-401-9000
Fax:
Address: 11 Hurley Street
Cambridge, MA 02141 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biological Product (except Diagnostic) Manufacturing
Clinical Gene Editing
Gene-Editing Medicine Development
Clinical Testing
Contacts Description
James Mullen CEO/Chairman of the Board/Director/President
Michelle Robertson CFO/Chief Accounting Officer/Executive VP
See More
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2021 2020 2019 2018 2017 2016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
CRISPR
Cas9
Cpfl
Cas12s
EDIT-301
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: